Related Experiment Video
Updated: Sep 26, 2025
A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
Published on: March 8, 2022
Identification of Potential Biomarkers and Small Molecule Drugs for Cutaneous Melanoma Using Integrated Bioinformatic
Yong Liu1,2, Jiayi Sun1, Dongran Han1
1School of Life Science, Beijing University of Chinese Medicine, Beijing, China.
Abstract:
Background: Cutaneous melanoma (CM) is a type of skin cancer with a high fatality rate, and its pathogenesis has not yet been fully elucidated. Methods: We obtained the gene expression datasets of CM through the Gene Expression Omnibus (GEO) database. Subsequently, robust rank aggregation (RRA) method was used to identify differentially expressed genes (DEGs) between CM cases and normal skin controls. Gene functional annotation was performed to explore the potential function of the DEGs. We built the protein-protein interaction (PPI) network by the Interactive Gene database retrieval tool (STRING) and selected hub modules by Molecular Complexity Detection (MCODE). We furthered and validated our results using the TCGA-GTEX dataset. Finally, potential small molecule drugs were predicted by CMap database and verified by molecular docking method. Results: A total of 135 DEGs were obtained by RRA synthesis analysis. GMPR, EMP3, SLC45A2, PDZD2, NPY1R, DLG5 and ADH1B were screened as potential targets for CM. Furazolidone was screened as a potential small molecule drug for the treatment of CM, and its mechanism may be related to the inhibition of CM cell proliferation by acting on GMPR. Conclusion: We identified seven prognostic therapeutic targets associated with CM and furazolidone could be used as a potential drug for CM treatment, providing new prognostic markers, potential therapeutic targets and small molecule drugs for the treatment and prevention of CM.
Insights
This study identifies seven key genes as potential therapeutic targets for cutaneous melanoma (CM). Furazolidone is proposed as a novel drug to treat CM by inhibiting cancer cell growth.
Area of Science:
- Oncology
- Genomics
- Bioinformatics
Background:
- Cutaneous melanoma (CM) is an aggressive skin cancer with poorly understood pathogenesis.
- High fatality rates underscore the need for novel therapeutic targets and treatment strategies.
Purpose of the Study:
- To identify differentially expressed genes (DEGs) in CM.
- To explore potential therapeutic targets and small molecule drugs for CM treatment.
Main Methods:
- Utilized Gene Expression Omnibus (GEO) datasets for CM.
- Applied robust rank aggregation (RRA) to identify DEGs.
- Constructed protein-protein interaction (PPI) networks and performed functional annotation.
- Validated findings using TCGA-GTEX data and predicted drugs via CMap, confirmed by molecular docking.
Main Results:
- Identified 135 DEGs in CM.
- Screened seven genes (GMPR, EMP3, SLC45A2, PDZD2, NPY1R, DLG5, ADH1B) as potential CM targets.
- Furazolidone identified as a potential drug, possibly acting on GMPR to inhibit CM cell proliferation.
Conclusions:
- Seven prognostic therapeutic targets for CM were identified.
- Furazolidone shows promise as a potential therapeutic agent for CM treatment.
- This research offers new prognostic markers, therapeutic targets, and drug candidates for CM management.
More Related Videos
07:41Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases
Published on: May 17, 2019
07:47Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
Published on: September 15, 2023